Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)

Ironwood Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases. Its lead product Linzess (linaclotide) is approved for irritable bowel syndrome with constipation and chronic idiopathic constipation in multiple regions. The company also advances apraglutide a peptide analog of glucagon like peptide 2 for short bowel syndrome patients dependent on parenteral support. Ironwood Pharmaceuticals Inc was incorporated in Delaware in 1998 and changed its name to the current form in 2008.

Ironwood Pharmaceuticals Inc generates revenue primarily through collaborative arrangements with partners that commercialize Linzess in the United States and abroad. In the United States the company shares profits with AbbVie and records collaborative revenue based on Linzess sales. Outside the United States the company receives royalties and milestone payments from partners such as AstraZeneca in China and Astellas in Japan. The company also may receive upfront payments and development milestones from licensing agreements. Revenue is driven by prescription demand pricing and reimbursement dynamics.

Ironwood Pharmaceuticals Inc holds a leading position in the constipation therapy market with Linzess ranked as the number one prescribed branded treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation in the United States according to IQVIA data. The drug competes against over the counter laxatives and other prescription agents such as lubiprostone plecanatide prucalopride and tenapanor. For its pipeline candidate apraglutide the company faces competition from established therapies like teduglutide and emerging agents such as glepaglutide. Competitive advantages include a strong patent portfolio covering linaclotide formulations and a first in class mechanism of action for Linzess as well as deep expertise in gastrointestinal drug development.

Ironwood Pharmaceuticals Inc serves patients suffering from gastrointestinal disorders such as irritable bowel syndrome with constipation chronic idiopathic constipation and functional constipation. The company also targets patients with short bowel syndrome who are dependent on parenteral support. Its therapies are prescribed by gastroenterologists and primary care physicians and are distributed through retail pharmacies and specialty distributors. Key commercial partners include AbbVie AstraZeneca Astellas and others who assist in bringing the medicines to patients worldwide.